[8-K] Lipocine Inc. Reports Material Event

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Lipocine Inc. filed a current report describing a scientific presentation rather than a financial event. On May 26, 2026, the company presented Phase 3 clinical data for LPCN 1154, an oral brexanolone candidate for treating postpartum depression, at the American Society of Clinical Psychopharmacology Annual Meeting in Miami Beach.

The presentation and a related scientific poster, which summarize results from a placebo-controlled Phase 3 clinical trial in postpartum depression, are included as Exhibits 99.1 and 99.2 to the report and incorporated by reference for full clinical details.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

ASCP meeting dates: May 26–29, 2026 Exhibit 99.1: Clinical presentation Exhibit 99.2: Clinical poster

3 metrics

ASCP meeting dates May 26–29, 2026 American Society of Clinical Psychopharmacology Annual Meeting

Exhibit 99.1 Clinical presentation Phase 3 LPCN 1154 postpartum depression trial

Exhibit 99.2 Clinical poster Phase 3 LPCN 1154 postpartum depression trial

Key Terms

Phase 3 clinical trial, postpartum depression, oral brexanolone, American Society of Clinical Psychopharmacology, +1 more

5 terms

Phase 3 clinical trial medical

"Phase 3 placebo-controlled trial evaluating LPCN 1154 for the treatment of postpartum depression"

A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.

postpartum depression medical

"clinical trial of LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD)"

A mood disorder that can arise after childbirth, characterized by persistent sadness, anxiety, exhaustion and difficulty caring for oneself or a baby; it can range from moderate to severe and often requires medical or therapeutic treatment. Investors care because its prevalence affects demand for medical treatments, mental-health services and parental workplace policies, and can influence healthcare spending, drug development programs, and productivity in sectors that depend on caregiver labor — much like a widespread recurring expense that changes consumer and employer behavior.

oral brexanolone medical

"Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression"

Oral brexanolone is a pill form of a brain-active steroid-like medication designed to quickly reduce certain types of severe depression by calming overactive stress and mood circuits. For investors it matters because an oral formulation can be taken at home rather than given by IV in a clinic, potentially expanding the number of patients, lowering treatment delivery costs, and changing revenue and prescribing patterns for companies developing or selling the drug.

American Society of Clinical Psychopharmacology medical

"at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting held May 26th through the 29th, 2026"

neuroactive steroid medical

"Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154"

Neuroactive steroids are naturally occurring or lab-made molecules related to steroid hormones that change how brain cells send and receive signals, acting like a dimmer switch for neural activity. They matter to investors because they’re being developed as medicines for conditions such as mood, sleep, seizure, and neurodegenerative disorders, so trial results, regulatory decisions, manufacturing scale and safety news can strongly affect a drugmaker’s value and market opportunity.

Understanding 8-K Material Events →

05/26/2026 - 05:08 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 26, 2026

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware

99-0370688

(State or other jurisdiction

of incorporation)

(IRS Employer

Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events

On May 26, 2026, the Company presented its Phase 3 clinical data for LPCN 1154 and a poster at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting held May 26^th through the 29^th, 2026 in Miami Beach, FL. The presentation highlighted the results from Lipocine’s Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD). The presentation and poster are furnished as Exhibit 99.1 and 99.2 to this report and are incorporated by reference herein.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

The following exhibits are filed with this report:

Exhibit No.		Description

99.1		Presentation entitled “Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154”

99.2		Poster entitled “Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154”

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.